GlassScriptPhysician profile
Angela Pap
NPI 1477550838
$3,606.54
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $775 · 2020: $66.09 · 2021: $216 · 2022: $1,005 · 2023: $1,043 · 2024: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,543.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $893.39 | 2019-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $590.68 | 2019-2024 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $563.16 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $366.00 | 2021-2024 | |
| Lilly USA, LLC | $233.81 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.84 | 2021-2024 | Jardiance, Stiolto Respimat |
| Pfizer INC. | $176.32 | 2020-2024 | |
| Abbott Laboratories | $132.32 | 2019-2023 | Freestyle Libre 3 |
| Amgen INC. | $129.54 | 2019-2023 | Prolia, Evenity, Repatha |
| Dynavax Technologies Corporation | $56.01 | 2022 | |
| Sanofi-Aventis U.S. LLC | $53.43 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $39.43 | 2022-2024 | Gardasil, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.84 | 2019 | |
| Allergan, INC. | $24.29 | 2019 | |
| Shire North American Group INC | $21.51 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $20.41 | 2019 | |
| Dexcom, INC. | $16.97 | 2023 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $14.35 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.48 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $13.46 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.30 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Pap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.